StockData
IDEXX Laboratories Inc logo

IDEXX Laboratories Inc (IDXX) stock

IDXXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 19/3036% above fair value
$690.24−10.41 (-1.49%)

Close on Nov 17, 2026Market cap $54.38BP/E 48.5Yield –

IDEXX Laboratories r&d expenses

Research and development expenses are spending on new products and technology.

IDEXX Laboratories's R&D Expenses for the twelve months ending Jun 30, 2026 was $261.47M, up 12.4% year over year. For fiscal 2025 it was $251.21M, up 14.3% from the year before. Over ten years it grew 9.7% a year on average. The highest annual figure on record is $254.82M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$251.21M+14.3%
FY2024Dec 31, 2024$219.79M+15.1%
FY2023Dec 31, 2023$190.95M-25.1%
FY2022Dec 31, 2022$254.82M+58.3%
FY2021Dec 31, 2021$161.01M+14.0%
FY2020Dec 31, 2020$141.25M+6.0%
FY2019Dec 31, 2019$133.19M+13.0%
FY2018Dec 31, 2018$117.86M+8.0%
FY2017Dec 31, 2017$109.18M+8.0%
FY2016Dec 31, 2016$101.12M+1.4%
FY2015Dec 31, 2015$99.68M+1.4%
FY2014Dec 31, 2014$98.26M+11.7%
FY2013Dec 31, 2013$88.00M+7.3%
FY2012Dec 31, 2012$82.01M+7.9%
FY2011Dec 31, 2011$76.04M+10.9%
FY2010Dec 31, 2010$68.60M+5.3%
FY2009Dec 31, 2009$65.12M-7.9%
FY2008Dec 31, 2008$70.67M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$65.43M+5.7%
Q1 FY2026Mar 31, 2026$65.79M+11.4%
Q4 FY2025Dec 31, 2025$66.83M+15.8%
Q3 FY2025Sep 30, 2025$63.42M+17.5%
Q2 FY2025Jun 30, 2025$61.90M+11.6%
Q1 FY2025Mar 31, 2025$59.06M+12.2%
Q4 FY2024Dec 31, 2024$57.73M+11.4%
Q3 FY2024Sep 30, 2024$53.98M+12.5%
Q2 FY2024Jun 30, 2024$55.45M+19.2%
Q1 FY2024Mar 31, 2024$52.64M+17.8%
Q4 FY2023Dec 31, 2023$51.81M+19.3%
Q3 FY2023Sep 30, 2023$47.97M-0.1%
Q2 FY2023Jun 30, 2023$46.51M-62.3%
Q1 FY2023Mar 31, 2023$44.67M+11.2%
Q4 FY2022Dec 31, 2022$43.42M-4.2%
Q3 FY2022Sep 30, 2022$48.01M+18.8%
Q2 FY2022Jun 30, 2022$123.22M+226.9%
Q1 FY2022Mar 31, 2022$40.17M+6.9%
Q4 FY2021Dec 31, 2021$45.31M+16.8%
Q3 FY2021Sep 30, 2021$40.43M+7.8%
Q2 FY2021Jun 30, 2021$37.70M+19.1%
Q1 FY2021Mar 31, 2021$37.58M+12.8%
Q4 FY2020Dec 31, 2020$38.78M+10.3%
Q3 FY2020Sep 30, 2020$37.52M+9.5%
Q2 FY2020Jun 30, 2020$31.65M-1.9%
Q1 FY2020Mar 31, 2020$33.31M+5.7%
Q4 FY2019Dec 31, 2019$35.16M+16.7%
Q3 FY2019Sep 30, 2019$34.26M+17.4%
Q2 FY2019Jun 30, 2019$32.26M+9.3%
Q1 FY2019Mar 31, 2019$31.51M+8.6%
Q4 FY2018Dec 31, 2018$30.14M+4.6%
Q3 FY2018Sep 30, 2018$29.19M+5.8%
Q2 FY2018Jun 30, 2018$29.51M+9.3%
Q1 FY2018Mar 31, 2018$29.02M+12.5%
Q4 FY2017Dec 31, 2017$28.81M+13.3%
Q3 FY2017Sep 30, 2017$27.59M+7.5%
Q2 FY2017Jun 30, 2017$27.00M–
Q1 FY2017Mar 31, 2017$25.79M–
Q4 FY2016Dec 31, 2016$25.42M–
Q3 FY2016Sep 30, 2016$25.67M–

More IDEXX Laboratories figures

See a number that looks wrong?